Skip Nav Destination
Issues
15 July 2022
-
Cover Image
Cover Image
Live cell imaging of HEK 293T cells with confocal microscopy demonstrating localization of GFP-tagged OCLN-RASGRF1 (green) to the plasma membrane (red). For details, see the article by Hunihan and colleagues on page 3091 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy
Emily Y. Jen; Xin Wang; Meng Li; Hongshan Li; Shwu-Luan Lee; Nina Ni; Donna Przepiorka; Jonathon Vallejo; Ruby Leong; Lian Ma; Brenda J. Gehrke; Sherita McLamore; Marc R. Theoret; R. Angelo de Claro
Review
Clinical Trials: Targeted Therapy
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
Martin Schuler; Lisa Zimmer; Kevin B. Kim; Jeffrey A. Sosman; Paolo A. Ascierto; Michael A. Postow; Filip Y.F.L. De Vos; Carla M.L. van Herpen; Matteo S. Carlino; Douglas B. Johnson; Carola Berking; Micaela B. Reddy; Allison S. Harney; Jordan D. Berlin; Rodabe N. Amaria
Clinical Trials: Immunotherapy
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Mojun Zhu; Chunhua Chen; Nathan R. Foster; Christopher Hartley; Taofic Mounajjed; Marcela A. Salomao; Briant F. Fruth; Staci E. Beamer; Yohan Kim; Susan M. Harrington; Henry C. Pitot; Cristobal T. Sanhueza; Yening Feng; Joerg Herrmann; Robert R. McWilliams; Fabrice Lucien; Bing Q. Huang; Wen Wee Ma; Tanios S. Bekaii-Saab; Haidong Dong; Dennis Wigle; Daniel H. Ahn; Chris L. Hallemeier; Shanda Blackmon; Harry H. Yoon
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Martin H. Voss; Arun A. Azad; Aaron R. Hansen; Jhanelle E. Gray; Sarah J. Welsh; Xuyang Song; Michael Kuziora; Lina Meinecke; Jorge Blando; Ikbel Achour; Yi Wang; Farzana L. Walcott; Sjoukje F. Oosting
Neoantigen Identification and Response to Adoptive Cell Transfer in Anti–PD-1 Naïve and Experienced Patients with Metastatic Melanoma
Shoshana T. Levi; Amy R. Copeland; Shirley Nah; Jessica S. Crystal; Gabriel D. Ivey; Almin Lalani; Mohammad Jafferji; Bradley S. White; Neilesh B. Parikh; Vid Leko; Sri Krishna; Frank Lowery; Todd D. Prickett; Jared J. Gartner; Li Jia; Yong F. Li; Abraham Sachs; Sivasish Sindiri; Welles Robinson; Billel Gasmi; James C. Yang; Stephanie L. Goff; Steven A. Rosenberg; Paul F. Robbins
An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors
Jitka Fucikova; Michal Hensler; Lenka Kasikova; Tereza Lanickova; Josef Pasulka; Jana Rakova; Jana Drozenova; Tessa Fredriksen; Marek Hraska; Tereza Hrnciarova; Klara Sochorova; Daniela Rozkova; Ludek Sojka; Pavel Dundr; Jan Laco; Tomas Brtnicky; Ivan Praznovec; Michael J. Halaska; Lukas Rob; Ales Ryska; An Coosemans; Ignace Vergote; David Cibula; Jirina Bartunkova; Jérôme Galon; Lorenzo Galluzzi; Radek Spisek
Precision Medicine and Imaging
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Ning Zhao; Shalini Chopra; Kai Trepka; Yung-Hua Wang; Sasank Sakhamuri; Nima Hooshdaran; Hyunjung Kim; Jie Zhou; Shion A. Lim; Kevin K. Leung; Emily A. Egusa; Jun Zhu; Li Zhang; Adam Foye; Renuka Sriram; Emily Chan; Youngho Seo; Felix Y. Feng; Eric J. Small; Jonathan Chou; James A. Wells; Rahul Aggarwal; Michael J. Evans
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
John D. Martin; Ryan M. Lanning; Vikash P. Chauhan; Margaret R. Martin; Ahmed S. Mousa; Walid S. Kamoun; Hee-Sun Han; Hang Lee; Triantafyllos Stylianopoulos; Moungi G. Bawendi; Dan G. Duda; Edward B. Brown; Timothy P. Padera; Dai Fukumura; Rakesh K. Jain
Translational Cancer Mechanisms and Therapy
RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition
Lisa Hunihan; Dejian Zhao; Heather Lazowski; Man Li; Yuping Qian; Laura Abriola; Yulia V. Surovtseva; Viswanathan Muthusamy; Lynn T. Tanoue; Bonnie E. Gould Rothberg; Kurt A. Schalper; Roy S. Herbst; Frederick H. Wilson
Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer
Beshara Sheehan; Antje Neeb; Lorenzo Buroni; Alec Paschalis; Ruth Riisnaes; Bora Gurel; Veronica Gil; Susana Miranda; Mateus Crespo; Christina Guo; Juan Jiménez Vacas; Ines Figueiredo; Ana Ferreira; Jon Welti; Wei Yuan; Suzanne Carreira; Adam Sharp; Johann de Bono
Release of IFNγ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells
Giulia Corradi; Barbara Bassani; Giorgia Simonetti; Sabina Sangaletti; Jayakumar Vadakekolathu; Maria Chiara Fontana; Martina Pazzaglia; Alessandro Gulino; Claudio Tripodo; Gianluca Cristiano; Lorenza Bandini; Emanuela Ottaviani; Darina Ocadlikova; Milena Piccioli; Giovanni Martinelli; Mario Paolo Colombo; Sergio Rutella; Michele Cavo; Marilena Ciciarello; Antonio Curti
Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma
Crismita Dmello; Aarón Sonabend; Victor A. Arrieta; Daniel Y. Zhang; Deepak Kanojia; Li Chen; Andrew Gould; Jiangshan Zhang; Seong Jae Kang; Jan Winter; Craig Horbinski; Christina Amidei; Balázs Győrffy; Alex Cordero; Catalina Lee Chang; Brandyn Castro; Patrick Hsu; Atique U. Ahmed; Maciej S. Lesniak; Roger Stupp; Adam M. Sonabend
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.